Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | -2.74% | -12.88% | +61.36% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 184M |
---|---|---|---|---|---|
Net income 2024 * | -32M | Net income 2025 * | -39M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.68
x | P/E ratio 2025 * |
-4.9
x | Employees | 12 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.9% |
Latest transcript on Atossa Therapeutics, Inc.
1 day | -2.74% | ||
1 week | -11.25% | ||
Current month | -5.96% | ||
1 month | -7.19% | ||
3 months | +37.86% | ||
6 months | +75.37% | ||
Current year | +61.36% |
Managers | Title | Age | Since |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 08-11-30 |
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Heather Rees
DFI | Director of Finance/CFO | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Director/Board Member | 66 | 14-02-28 | |
H. Remmel
BRD | Director/Board Member | 72 | 12-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 1.42 | -2.74% | 1,211,143 |
24-05-24 | 1.46 | 0.00% | 855,521 |
24-05-23 | 1.46 | -4.58% | 1,164,057 |
24-05-22 | 1.53 | -6.13% | 1,227,945 |
24-05-21 | 1.63 | +1.87% | 972,665 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.36% | 184M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- ATOS Stock